Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers
Yang Sun,Xiang Zhang,Dong Hang,Harry Cheuk-Hay Lau,Jie Du,Chuanfa Liu,Mingxu Xie,Yasi Pan,Le Wang,Cong Liang,Xingyu Zhou,Danyu Chen,Jiamei Rong,Zengren Zhao,Alvin Ho-Kwan Cheung,Yuet Wu,Hongyan Gou,Chi Chun Wong,Lingbin Du,Junliang Deng,Zhibin Hu,Hongbing Shen,Yinglei Miao,Jun Yu
DOI: https://doi.org/10.1016/j.ccell.2024.07.005
IF: 50.3
2024-08-12
Cancer Cell
Abstract:Changes in plasma and fecal metabolomes in colorectal cancer (CRC) progression (normal-adenoma-CRC) remain unclear. Here, plasma and fecal samples were collected from four independent cohorts of 1,251 individuals (422 CRC, 399 colorectal adenoma [CRA], and 430 normal controls [NC]). By metabolomic profiling, signature plasma and fecal metabolites with consistent shift across NC, CRA, and CRC are identified, including CRC-enriched oleic acid and CRC-depleted allocholic acid. Oleic acid exhibits pro-tumorigenic effects in CRC cells, patient-derived organoids, and two murine CRC models, whereas allocholic acid has opposing effects. By integrative analysis, we found that oleic acid or allocholic acid directly binds to α-enolase or farnesoid X receptor-1 in CRC cells, respectively, to modulate cancer-associated pathways. Clinically, we establish a panel of 17 plasma metabolites that accurately diagnoses CRC in a discovery and three validation cohorts (AUC = 0.848-0.987). Overall, we characterize metabolite signatures, mechanistic significance, and diagnostic potential of plasma and fecal metabolomes in CRC.